Sanofi (EPA:SAN) has been assigned a €83.00 ($102.47) price target by equities research analysts at Kepler Capital Markets in a report released on Tuesday. The firm currently has a “buy” rating on the stock. Kepler Capital Markets’ target price would indicate a potential upside of 22.17% from the stock’s previous close.
A number of other research firms have also recently commented on SAN. S&P Global set a €78.00 ($96.30) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Tuesday, January 23rd. JPMorgan Chase & Co. reissued a “neutral” rating and set a target price on shares of Sanofi in a research report on Thursday, November 2nd. Goldman Sachs Group set a €82.00 ($101.23) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Monday, January 29th. Berenberg Bank set a €97.00 ($119.75) target price on shares of Sanofi and gave the stock a “neutral” rating in a research report on Thursday, November 2nd. Finally, Deutsche Bank set a €96.00 ($118.52) target price on shares of Sanofi and gave the stock a “buy” rating in a research report on Wednesday, October 18th. One research analyst has rated the stock with a sell rating, ten have given a hold rating and five have given a buy rating to the company’s stock. The company currently has an average rating of “Hold” and an average target price of €85.50 ($105.56).
Sanofi (EPA:SAN) opened at €67.94 ($83.88) on Tuesday. Sanofi has a 12-month low of €67.36 ($83.16) and a 12-month high of €92.97 ($114.78). The company has a market cap of $85,820.00 and a price-to-earnings ratio of 18.82.
COPYRIGHT VIOLATION NOTICE: “Sanofi (SAN) Given a €83.00 Price Target by Kepler Capital Markets Analysts” was first published by Stock Observer and is the property of of Stock Observer. If you are accessing this story on another site, it was stolen and reposted in violation of US & international trademark and copyright law. The original version of this story can be read at https://www.thestockobserver.com/2018/02/06/sanofi-san-given-a-83-00-price-target-by-kepler-capital-markets-analysts.html.
Sanofi is a healthcare company, focused on patient needs and engaged in the research, development, manufacture and marketing of therapeutic solutions. Its segments are Pharmaceuticals, Human Vaccines (Vaccines), and Other. The Pharmaceuticals segment comprises the commercial operations of various franchises, including Speciality Care (Rare Diseases, Multiple Sclerosis, and Oncology), Diabetes and Cardiovascular, Established Prescription Products, Consumer Healthcare and Generics, and research and development, production and marketing activities for all of the Company’s pharmaceuticals operations.
Receive News & Ratings for Sanofi Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sanofi and related companies with MarketBeat.com's FREE daily email newsletter.